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There is a growing body of evidence that bilirubin, which is generated during the physiological breakdown of 
heme, exerts potent anti-inflammatory effects. Previous work by our group suggests that bilirubin is able to 
suppress inflammatory responses by preventing the migration of leukocytes into target tissues through 
disruption of vascular cell adhesion molecule-1 (VCAM-1)-dependent cell signaling. As VCAM-1 is an important 
mediator of tissue injury in the dextran sodium sulfate (DSS) murine model of inflammatory colitis, we 
examined whether bilirubin prevents colonic injury in DSS-treated mice. As anticipated, bilirubin-treated 
animals manifested significantly less colonic injury and reduced infiltration of inflammatory cells into colon 
tissues. We further observed that bilirubin administration was associated with a reduced number of eosinophils 
and monocytes in the small intestine, with a corresponding increase in peripheral blood eosinophilia, regardless 
of whether mice received DSS. These findings suggest that bilirubin impairs the normal migration of eosinophils 
into intestinal tissues, as supported by in vitro experiments showing that bilirubin blocks the 
VCAM-1-dependent movement of Jurkat cells across human endothelial cell monolayers. Taken together, our 
findings support that bilirubin ameliorates DSS-induced colitis and disrupts the physiological trafficking of 
leukocytes to the intestine by preventing transmigration across the vascular endothelium, potentially through the 
inhibition VCAM-1-mediated signaling. Our findings raise the possibility that bilirubin functions as an 
endogenous regulator of inflammatory responses. 
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In all mammalian species, bilirubin is generated during the 
normal physiological breakdown of heme through the 
sequential activity of the heme oxygenase and biliverdin 
reductase enzymes. It was first postulated over 75 years ago 
that bilirubin exerts anti-inflammatory effects when it was 
noted that patients with rheumatoid arthritis experienced 
remission after developing jaundice from superimposed liver 
disease [1, 2]. More recent epidemiological studies have 
correlated increased serum bilirubin levels with a decreased 
incidence of inflammatory conditions such as asthma [3], 
multiple sclerosis [4], and Crohn’s disease [5]. Experimentally, 
bilirubin has been shown to ameliorate tissue injury in 
murine models of allergen-induced inflammation, including 
experimental autoimmune encephalomyelitis [6] and allergic 
pneumonitis [7]. In the latter study, our group demonstrated 
that the administration of bilirubin via intraperitoneal  
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injection markedly suppressed allergen-induced pulmonary 
inflammation in immunoprimed mice, principally by 
preventing VCAM-1-mediated eosinophil infiltration into the 
lung. At the cellular level, we have further demonstrated that 
bilirubin, a potent chain-breaking antioxidant [8, 9], inhibits 
VCAM-1-dependent migration of leukocytes across 
endothelial monolayers by scavenging NADPH 
oxidase-generated reactive oxygen species [7], which are key 
intermediaries of endothelial cell retraction [10]. 
VCAM-1-mediated infiltration of eosinophils into the 
intestinal mucosa has been implicated in the pathogenesis of 
both ulcerative colitis and Crohn’s disease [11-13], and it has 
been shown that treatment of rodents with antibodies [14-16] or 
antisense oligonucleotides [17] directed against VCAM-1 
suppresses intestinal inflammation in colitis models. In 
humans, blocking antibodies directed against leukocyte 
integrins that bind VCAM-1 have been demonstrated to 
ameliorate Crohn’s disease [18, 19]. Based on our previous 
work indicating that bilirubin is able to disrupt 
VCAM-1-mediated endothelial cell signaling, we speculated 
that treating mice with this bile pigment would prevent 
colitis induced by DSS, which is a VCAM-1-dependent 
process [16], by preventing the migration of inflammatory 
cells across vascular endothelium. In the present study [20], 
we found that DSS-treated mice that are simultaneously 
administered i.p. bilirubin experience markedly diminished 
disease severity as compared with vehicle-treated animals. 
Concordant histopathological analyses revealed that 
bilirubin-treated mice manifested significantly less colonic 
injury in response to DSS, with a marked reduction in the 
infiltration of eosinophils, lymphocytes, and monocytes into 
the colon. As bilirubin previously has been shown not to alter 
the production of pro-inflammatory cytokines and 
chemokines [7], these findings support the hypothesis that 
bilirubin suppresses DSS-induced intestinal injury by 
inhibiting VCAM-1-mediated leukocyte migration into the 
colon. 
We further observed that mice receiving bilirubin 
Figure 1. Proposed mechanism of bilirubin modulation of VCAM-1-dependent 
leukocyte migration. As originally delineated by Cook-Mills et al. [10], the binding of 
leukocyte VLA4 to endothelial VCAM-1 triggers the calcium- and Rac1-dependent activation 
of NADPH oxidase (NOX), resulting in the production of superoxide (O2-) and hydrogen 
peroxide (H2O2). These reactive oxygen species (ROS) stimulate downstream activation of 
matrix metalloproteinases (MMP)-2 and -9, which leads to the disruption of endothelial tight 
junctions and facilitates leukocyte transmigration. Bilirubin, a membrane permeant [26] and 
highly potent chain-breaking antioxidant [9] that undergoes intracellular redox cycling (dotted 
lines) through the action of bilirubin reductase (BVR) [8], scavenges NOX-derived ROS 
signaling intermediaries [7, 27], thereby inhibiting endothelial retraction and leukocyte 
migration.  
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demonstrated reduced numbers of eosinophils in the small 
intestine, even in the absence of DSS treatment [20]. As 
eosinophils are primarily tissue resident cells [21], these data 
indicate that, in addition to preventing leukocyte recruitment 
in response to inflammatory stimuli, bilirubin also inhibits 
the normal physiological trafficking of eosinophils to the 
gastrointestinal tract. This conclusion is supported by the 
coincident increase in peripheral blood eosinophilia detected 
in bilirubin-treated animals. We further noted that bilirubin 
administration was associated with reduced levels of 
monocytes in the small intestine, while the number of 
T-lymphocytes remained unaltered [20]. These findings 
suggest that eosinophils and monocytes may share a similar 
mechanism of recruitment to the small bowel. At the cellular 
level, we also demonstrated that bilirubin, at physiological 
concentrations (≤ 20 µM), prevents the migration of Jurkat cells 
(a T-cell leukemia line) across monolayers of human umbilical 
vein endothelial cells [20]. Since this process has been shown 
to be predominantly VCAM-1-mediated [22, 23], these data 
provide additional support for the proposition that bilirubin 
impedes leukocyte homing to target tissues by disrupting 
endothelial VCAM-1 signaling.  
As VCAM-1 is an important mediator of leukocyte 
recruitment that occurs in response to certain infections and 
other inflammatory conditions [10], it stands to reason that 
bilirubin may act to attenuate these disorders. In support of 
this hypothesis are epidemiological analyses that have 
correlated increased serum bilirubin levels with a decreased 
incidence of certain disorders in which VCAM-1 has been 
shown to play a pathogenic role, including asthma [3], 
multiple sclerosis [4], and coronary artery disease [24, 25]. Our 
investigations support a mechanism of bilirubin action that 
involves the inhibition of VCAM-1-dependent leukocyte 
translocation across vascular endothelia through the 
scavenging of reactive oxygen species signaling 
intermediaries (Figure 1). We speculate that bilirubin, 
produced by the action of heme oxygenase-1 (which is 
induced in response to pro-inflammatory stimuli), serves as 
an endogenous regulator of host inflammatory responses.  
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